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Abstract We have studied the pharmacological properties of 
genetically engineered human NK, tachykinin receptors in which 
residues at the extracellular surface of the fourth transmem-
branal domain were substituted with the corresponding amino 
acids from the NK2 receptor. We show that substitution of 
G166C:Y167F in the human ΝΚχ receptor induces high affinity 
binding of a group of tachykinin ligands, known as 'septides' (i.e. 
neurokinin A, neurokinin B, [pGlue,Pro9]-substance ρβ η and 
substance P-methylester). In contrast, binding of substance P 
and non-peptide antagonists is unaffected by these mutations. 
This effect parallels that found on the rat receptor and is 
therefore species specific. Second, we demonstrate that mutation 
of Gly166 to Cys alone is both necessary and sufficient to create 
this pan-reactive tachykinin receptor, whereas replacement of 
Tyr167 by Phe has no detectable effect on the pharmacological 
properties of the receptor. Furthermore, analysis of the effect of 
./V-ethylmaleimide and dithiothreitol on binding of radiolabelled 
substance P documents differences in the mode in which this 
ligand interacts with wild-type and mutant receptors and 
supports the existence of a mutational induced change in the 
conformational status of the ΝΚχ receptor. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Mammalian tachykinins (SP, NKA and NKB) exert their 
physiological effects through activation of three distinct sub-
types of receptors originally termed the substance P (NK4), 
the substance К (NK2) and the neurokinin В (NK3) receptors 
[1,2]. Each peptide hormone is considered the preferential en-
dogenous ligand for the respective receptor and this selectivity 
is believed to arise from subtype specific interactions between 
divergent residues in the N-terminal part of the peptides and 
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variant elements in the receptor molecules. The preserved C-
terminus of tachykinins constitutes a prerequisite for binding 
to the receptor, and its possible interaction with common 
epitopes in the NKi receptors has been proposed as the mo-
lecular basis underlying the significant crossreactivity ob-
served within this system [3,4]. 
Various lines of evidence, however, indicate that this para-
digm is too simplified. First, it is possible to build affinities 
and selectivities comparable or even greater than those of 
natural tachykinins into the fundamental C-terminal core el-
ement of these peptide ligands [5]. Second, receptor specificity 
for peptidic ligands may be essentially obliterated by substi-
tutions of single or multiple residues that presumably change 
the conformation of the receptor molecule rather than affect-
ing direct ligand receptor interactions [6-8]. 
In analogy to selectivity for peptide ligands, a number of 
non-peptidic antagonists display a dramatic species specificity 
towards various NKi receptors. A few key residues that likely 
do not form part of the docking site, have been shown to 
regulate the ability of the receptor molecule to bind these 
ligands through an indirect effect on receptor conformation 
[9-12]. 
Thus, control of the receptor conformation may constitute 
the principal mechanism that regulates affinity and selectivity 
in the tachykinin system. The interesting question is whether 
NKi binding is subject to a single central regulatory mecha-
nism that governs overall affinity and selectivity or rather that 
multiple control systems exist. If so, do such mechanisms, 
controlled by physically separate sites in the receptor, operate 
in functional independent or interrelated modes? 
We have recently identified a site in the rat NKi receptor 
which is important for the recognition and selectivity of ta-
chykinin peptides [6]. Mutation of this epitope abolishes se-
lectivity and results in receptor that binds SP, heterologous 
tachykinins as well as modified SP analogues with high affinity 
[6,13]. 
To investigate the mechanisms underlying the recognition 
and discrimination in the tachykinin system both multiple and 
single substitutions of residues at the interface between the 
fourth transmembranal domain and the second extracellular 
loop on the NKi receptor were analyzed. We show that these 
mutations affect selectivity towards peptidic ligands without 
changing specificity for non-peptides, and demonstrate that 
this effect is independent of the species related differences in 
structure among NKi receptors. Furthermore we identify the 
single amino acid substitution affecting receptor selectivity 
and present evidence which supports the notion that the mu-
tation does induce a change in receptor conformation which 
may be detected also for binding of the otherwise mutation-
ally inert SP ligand. 
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2. Materials and methods 
2.1. Materials 
Monoiodinated 125I-labelled Bolton-Hunter substance P ([125I]-SP), 
2000 Ci/mmol, and 2-125I-iodohistidyl neurokinin A ([125I]-NKA), 
2000 Ci/mmol, were purchased from Amersham. All peptides were 
obtained from Sigma or Novabiochem. SR140333 [14] was kindly 
provided by Dr. Emond-Alt, Senofi Recherche. FK888 [15] was syn-
thesized in the Department of Chemistry, Menarini Ricerche Sud. 
2.2. Construction of mutant receptors 
The cDNA encoding the human NKi receptor was kindly provided 
by Dr. Schwartz, University of Copenhagen. The cDNA was sub-
cloned into the replicative form of M13mpl9 DNA, and site-directed 
mutagenesis performed using the oligonucleotide-directed in vitro muta-
genesis system from Amersham according to the instructions of the 
supplier. The oligonucleotides used were: the C166G mutation 5'-
ggccttcccccagtgctactactcaacc-3'; the Y167F mutation 5'-ccttcccccagg-
gcttctactcaaccac-3'; the G166C:Y167F mutation 5'-ggccttcceccagtg-
cttctactcaaccac-3'. They were purchased from Primm. The nucleotide 
sequence was verified by sequencing using the Sequenase sequencing 
system from U.S. Biochemical Corp. The cDNA was subsequently 
subcloned into the mammalian expression vector, pcDNA3 (Invitro-
gen). 
2.3. Cell culture and transfection 
COSI cells were grown in DMEM supplemented with 10% fetal calf 
serum, and CHO cells were grown in DMEM:F12 (1:1) supplemented 
with 10% fetal calf serum. COSI cells were transiently transfected as 
previously described [6]. Stable expression in CHO cells was obtained 
by transfection of cDNA encoding wild-type or mutant NKi recep-
tors using Lipofectamine (Gibco, BRL.) and stable expressing clones 
were identified following selection with 400 μg/ml G418 (Geneticin, 
Gibco, BRL). 
2.4. Binding assay 
Transiently or stable expressing cells were plated in 24 well plates 
and wild-type and mutant receptors characterized using [125I]-SP and 
[125I]-NKA as radioligand. Cells were incubated for 3 h at 4°C (until 
equilibrium) in presence of 10 pM radiolabelled substance P and in-
creasing concentrations of cold competing ligands in 0.5 ml of 50 mM 
HEPES (pH 7.4), 150 mM NaCl, 5 mM MnCl2, 0.1% BSA supple-
mented with bacitracin (100 μg/mΓ), leupeptin (5 μg/ml) and chymo-
statin (10 μg/ml) to prevent degradation. The incubation medium was 
removed and the cells washed with ice-cold phosphate-buffered saline. 
The monolayer was lysed in 0.5 ml of 4% SDS, 0.4 M NaOH and 
counted. All determinations were done in duplicate. 
2.5. Data analysis and statistics 
Equilibrium binding parameters were computed by the analysis of 
the binding isotherms according to the mass action law using non-
linear least squares fitting procedures with the computer program 
LIGAND (as described in [16]). All binding isotherms of a given 
experiment were fitted simultaneously; hence the data set of the ho-
mologous binding of radiolabelled and cold substance P as well as 
that of the heterologous competition between radiolabelled substance 
P and a given cold ligand were concurrently loaded into the computer 
program and used in the fitting routine. 
2.6. Effect ofNEM and DTT treatment 
CHO clones stably expressing wild-type or G166C mutant receptor 
were seeded in 24 well plates (2X 105 cells/well) and assayed after 24-
48 h essentially as described [17]. Briefly, the cells were incubated in 
HEPES buffer (20 mM HEPES (pH 7.4), 120 mM NaCl, 5 mM KC1, 
2.2 mM MgCl2, 1 mM CaCl2, 6 mg/ml glucose, 0.6 mg/ml BSA) 
containing NEM or DTT at indicated concentrations for 1 h at 4°C 
or 37°C, respectively. Cells were subsequently washed and incubated 
in radioligand buffer (10 pM [125I]-SP or [125I]-NKA in 0.5 ml HEPES 
buffer) at 4°C for 3 h to reach equilibrium. The cells were washed with 
PBS, lysed and counted as above. Specific binding was determined in 
the presence of excess cold SP. 
3. Results 
3.1. The G166C mutation of the human NKj receptor induces 
a selective increase of affinity for a class of NKA-like 
tachykinin ligands 
As observed previously for the rat receptor [6,13], the dou-
ble residue substitution of the human receptor greatly en-
hanced the affinity of the heterologous tachykinins, N K A 
and N K B , while it did not affect the binding of SP, and 
thus, resulted in a non-selective high affinity tachykinin recep-
tor (Table 1). N - and C-terminally modified SP analogues, 
such as septide and SP-methylester, also displayed a signifi-
cant increase in affinity for the mutan t receptor, whereas the 
mutan t affinities of the NK3 agonist, [MePhe7]-NKB and of 
the N K i receptor antagonists, FK888 and SR140333, were 
similar to those for wild-type receptors (Table 1). This double 
residue mutat ion, therefore, identifies two classes of neuroki-
nin ligands : the mutat ion sensitive NKA-like agonists and the 
mutat ion insensitive SP-like ligands, which include agonists 
and antagonists. To identify which of the two residues was 
responsible for this class specific change of affinity we pre-
pared and studied the corresponding single site mutations, 
Y167F and G166C of the N K i receptor: The Tyr to Phe 
transmutat ion of residue 167 resulted in little or no change 
in affinity for the set of studied ligands compared to wild-type 
N K i receptor (Table 1). In contrast, replacement of Gly by 
Cys in position 166, caused a change of binding affinities that 
was very similar to that observed for the G166C:Y167F dou-
Table 1 
Dissociation constants of tachykinin ligands for binding to wild-type, G166C, Y167F and G166C:Y167F NKi receptors 
Ligands 
SP 
NKA 
NKB 
SP-methylester 
Septide 
[Sar9]-SP 
[MePhe7]-NKB 
FK888 
SR140333 
Dissociation constants (K^) 
Wild-type 
(nM) 
0.53 
120 
310 
20 
250 
5.1 
420 
1.0 
4.8 
(ri) 
(9) 
(4) 
(4) 
(8) 
(7) 
(2) 
(2) 
(3) 
(3) 
G166C 
(nM) 
0.41 
6.5 
5.1 
1.3 
4.5 
3.8 
270 
0.23 
3.8 
(ri) 
(5) 
(5) 
(4) 
(2) 
(3) 
(2) 
(2) 
(2) 
(2) 
Y167F 
(nM) 
0.24 
54 
240 
45 
75 
4.7 
1200 
0.55 
6.2 
(ri) 
(4) 
(2) 
(2) 
(2) 
(2) 
(2) 
(2) 
(2) 
(2) 
G166C:Y167F 
(nM) 
0.40 
3.8 
3.4 
1.1 
20 
4.2 
360 
0.24 
1.8 
(n) 
(3) 
(2) 
(2) 
(2) 
(2) 
(2) 
(2) 
(2) 
(2) 
Ratio (wild-type/mutants) 
G166C 
1.3 
18 
61 
15 
56 
1.3 
1.6 
4.3 
1.3 
Y167F 
2.7 
2.2 
1.3 
4.4 
3.3 
1.1 
0.35 
1.7 
0.77 
G166C:Y167F 
1.4 
32 
91 
18 
13 
1.2 
1.2 
4.0 
2.7 
Binding isotherms for tachykinins and non-peptide ligands in competition for [125I]-SP were generated as described in Section 2. Data were analyzed 
with the computer program Ligand [15] to calculate binding affinities. Results are presented as nanomolar dissociation constants (Äj) and all 
reported data have a standard error of the mean lower than 25% which are not included in the table for clarity. The number of individual 
experiments (я) is indicated. The effect of the mutation is highlighted by taking the ratio between the affinities on wild-type the ΝΚχ receptor and 
each mutant receptor. 
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Fig. 1. Effect of NEM (panel A) and DTT (panel B) on binding of 
[125I]-SP on wild-type (open circles) and mutant (closed circles) NKi 
receptor. Specifically bound radioligand is expressed in percent of 
bound tracer in absence of NEM or DTT, and is the mean of three 
similar experiments. Error bars reporting the standard error of the 
mean is given in each point. X-axis is given in logarithm to the mo-
lar (M) concentrations of NEM and DTT. 
ble mutation. Thus, the glycine for cysteine substitution at 
position 166 in the NKi receptor is the necessary and suffi-
cient change to endow the NKi receptor with enhanced affin-
ity for NKA-like ligands. 
3.2. NEM and DTT differentially affects substance P binding 
to wild-type and mutant receptor 
It is known that the binding of SP to NKi receptor is 
sensitive to thiol reagents [17]. To further characterize the 
difference between wild-type and G166C mutant receptors, 
we examined the sensitivity of SP binding to wild-type and 
mutant receptors after exposure to increasing concentrations 
of either 7V-ethylmaleimide (NEM), or dithiothreitol (DTT). 
In cells expressing wild-type ΝΚχ receptor the binding of 
[125I]-SP was inhibited considerably more by NEM over a 
wide range of concentrations than in mutant expressing cells. 
Hence, as shown in Fig. 1A, 1 mM NEM inhibited 55% of SP 
binding on wild-type but only 35% on mutant NKi receptor. 
Fig. IB shows that also the effect of DTT discriminates be-
tween binding of [125I]-SP to wild-type and mutant receptors. 
However, these experiments document that the mutation ren-
ders SP binding to the receptor more sensitive to the action of 
337 
DTT. The application of sulfhyldryl reagents, therefore, al-
lows us to verify the mutational induced alteration in the 
receptor molecule. 
4. Discussion 
As shown previously, two-amino acid substitution in the 
extracellular surface of the fourth transmembranal helix of 
the rat NKi receptor selectively enhances the apparent bind-
ing affinity for a heterogeneous group of tachykinins [6,13], all 
of which share the ability to preferentially induce PI signaling 
rather than cAMP responses upon binding to NKi receptor 
[18]. The same mutation was found to potentiate selectively 
the ability of the NKj receptor to trigger PI signaling presum-
ably by shifting its G protein preference, which suggested that 
the replacement of two residues had an influence on the over-
all conformation of the molecule rather than only affecting the 
interactions at the ligand binding site [13]. 
In this study we report three additional observations that 
are important to understand the role of this locus in the ΝΚχ 
receptor and the mechanism of the change in binding affinity. 
The first relates to the significant differences in binding 
properties observed among NKi receptors from various spe-
cies. It has been shown previously that numerous tachykinin 
ligands, in particular non-peptide antagonists, greatly discrim-
inate between human and rat ΝΚχ receptors; a phenomenon 
that has been attributed to conformational differences be-
tween these receptors [9-12], and thus represents a naturally 
occurring system of conformational regulation of receptor se-
lectivity. We find that the double mutation affects specificity 
towards tachykinins independently of the species origin of the 
receptor and, hence, its ability to discriminate among non-
peptidic ligands, which suggests that affinity and selectivity 
in the tachykinin system are regulated through multiple indi-
rect and non-interrelated mechanisms that control conforma-
tion of the receptor molecule. 
The second point is the comparison of the binding charac-
teristics of the double mutation and the two single mutations 
performed here in the human NKi receptor. As shown here, 
the ability to induce a class specific increase of affinity for 
NKA-like tachykinins is entirely due the replacement of 
Gly166 by Cys, while mutation of the adjacent residue in posi-
tion 167 produces no detectable change. This indicates that 
Cys166 plays a primary role in the conformational change that 
results in enhanced affinity for the class of NKA-like ligands. 
Additional substitutions with other residues in this position 
will be necessary to clarify whether the introduction of a thiol 
function or other physicochemical properties of the replaced 
side-chain constitute the fundamental perturbation responsi-
ble for the phenomenon. 
It is important to note that a Gly by Cys replacement in 
position 166 occurs naturally in both the NK2 and NK3 re-
ceptor sequences and represents a non-conservative substitu-
tion with respect to the ΝΚχ receptor sequence. It can be 
hypothesized that this spontaneous mutation plays a potential 
role in the divergent ligand binding characteristics that the 
three tachykinin receptor subtypes have acquired in the course 
of evolution. The fact that the introduction of this single 
residue is sufficient to enhance the affinity in the NKi receptor 
for heterologous tachykinins to the point that the apparent 
binding selectivity for SP is largely abolished, strongly support 
this hypothesis. Since a similar class specific enhancement of 
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affinity have been reported following an Ala substitution of 
Tyr216 [7] or transplantation of a NK3 segment [8] in NKi 
receptors, it will be important to attempt to map such key 
regulatory elements in the receptor and study their interrelat-
edness by analyzing genetically engineered receptors bearing 
multiple mutations in these residues. Another important im-
plication of the finding that the mutation only affects one 
specific class of tachykinin ligands, is that these NKA-like 
agonists bind to the NKi receptor in a fundamentally differ-
ent manner than SP. 
A third finding of this study is that the mutational effect on 
ligand binding to NKi receptors and the perturbation induced 
by the G166C mutation can be easily underscored and inde-
pendently validated by chemical modification of the thiol 
groups in the NKi receptor. It was shown previously [17] 
that alkylation of NKi receptor by progressively increasing 
concentrations of NEM produces a complex pattern of inhib-
ition of ligand binding, which probably reflects the contribu-
tions of several cysteine residues in maintaining the ligand 
binding conformation of the receptor. Since the individual 
sensitivity to alkylation of thiol residues in the protein de-
pends on the microenvironment, which, in turn, can be altered 
by changes of conformations, we exploited NEM-mediated 
disruption of the binding interactions as a rough measurement 
of the effect of the mutation on the overall conformational 
stability of the NKi receptor. The data presented here indicate 
that the G166C mutation produces a clear cut shift in sensi-
tivity to NEM even when the binding is monitored by radio-
labelled SP, i.e. a ligand whose binding affinity is not altered 
by the mutation. This supports the idea that the mutation 
induces a conformational change of the receptor regardless 
of whether this can also be detected as a change of apparent 
binding affinity by some ligands and not by others. We also 
show here that mutant and wild-type receptors exhibit an 
opposite pattern of sensitivity to the action of the reducing 
agent DTT, indicating that both the reactivity of thiol groups 
and the resistance of disulfide bridges to reduction have been 
altered as a result of the conformational change promoted by 
the point mutation. The fact that the introduction of a single 
cysteine residue in the transmembrane region of the receptor 
can produce a global shift in the pattern of sensitivity to 
chemical modification of thiol groups is intriguing. We may 
speculate the introduction of Cys166 in the NKi receptor can 
alter the orientation of several thiol residues and even affect 
the configuration of possible disulfide bridges. Systematic mu-
tagenesis of additional cysteine residues and the assessment of 
their role in the binding of both SP-like and NKA-like ligands 
will be necessary to evaluate this hypothesis. 
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